

---

**2007 SCIENTIFIC SESSIONS DAY BY DAY PROGRAM**

# SATELLITE SYMPOSIUM

SUNDAY, MAY 6, 2007 • 12:30 PM TO 4:30 PM

PONCIANA 3 AND 4

---

## *Hypertension and the CardioMetabolic Syndrome Impact on the Hispanic Population*

**Chairs:** Claude Lenfant, M.D., Gaithersburg, Maryland, USA  
Luis Alcocer, M.D., Mexico City, Mexico

**Objectives:** At the conclusion of the activity, participants should be able to:

- Define hypertension and the components of the metabolic syndrome in South America.
- Describe the associated increase of obesity rates to hypertension and cardiovascular morbidity.
- Identify prevalence and incidence of hypertension and diabetes in Hispanics.
- Assess genetic determinants of the metabolic syndrome and response to treatment.
- List the critical questions from population studies about hypertension and the metabolic syndrome.
- Identify the elements of a systematic approach for chronic kidney disease in the metabolic syndrome.
- Define the economic variables that influence the prevalence of the metabolic syndrome.
- Describe the hemodynamic bases of the patterns of hypertension in Peruvian Andeans.
- Summarize the epidemiological analysis of hypertension.
- Describe the public health implications of the Hispanic Paradox.

### PROGRAM AGENDA

- 1:00 PM Welcome and Overview**  
*Claude Lenfant, M.D., Gaithersburg, Maryland, USA*
- 1:20 PM Obesity and the CardioMetabolic Syndrome**  
*Paulo A. Lotufo, M.D., Ph.D., Sao Paulo, Brazil*
- 1:40 PM CardioMetabolic Syndrome in Puerto Rico**  
*Jose Cangiano, M.D., San Juan, Puerto Rico*
- 2:00 PM Hypertension and the CardioMetabolic Syndrome in Chile-First Chilean National Health Survey**  
*Paula Margozzini, M.D., Santiago, Chile*
- 2:20 PM Renal Health Models for Latin America**  
*Rafael Burgos Calderon M.D., San Juan, Puerto Rico*
- 2:40 PM BREAK**
- 3:00 PM Micro-economic Impact of the Metabolic Syndrome**  
*Luis Alcocer, M.D., Mexico City, Mexico*
- 3:20 PM Hypertension Pattern in Peruvian Andeans-The PREVENCIÓN Study**  
*Julio A. Chirinos, M.D., Miami, Florida, USA*
- 3:40 PM Hypertension and the CardioMetabolic Syndrome: Hispanic Paradox Lost?**  
*Edward Roccella, Ph.D., M.P.H., Bethesda, Maryland, USA*
- 4:00 PM Questions and Answers**  
*Panel Discussion*
- 4:30 PM ADJOURN**

---

*Buffet Lunch will be held from 12:30 PM-1:00 PM in hallway outside of Ponciana*

**OPENING CEREMONY - XVII MEETING  
INTER-AMERICAN SOCIETY OF HYPERTENSION  
AMERICANA 4**

---

**5:00 PM..... ENTERTAINMENT**

**5:30 PM-6:30 PM..... WELCOME AND INTRODUCTION**

Carlos M. Ferrario, M.D. and Leopold Rajj, M.D.  
Chairs - 2007 IASH Scientific Sessions  
Recognition of the 2007 IASH Planning Committee

**WELCOME FROM THE UNIVERSITY OF MIAMI**

**IASH PRESIDENT'S ADDRESS**

Ernesto L. Schiffrin, M.D., Ph.D.

Recognition of Endorsements and Participating Officers from  
American Continent Societies and Europe-Asia Organizations

# DINNER SYMPOSIUM I

SUNDAY, MAY 6, 2007 • 7:00 PM TO 9:00 PM

PONCIANIA 3 AND 4

---

## *Combination Therapy*

**Chair:** Carlos Ferrario, M.D., Winston-Salem, North Carolina, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Define combination therapy.
- Summarize the rationale for using combination therapy.
- Articulate the differences in using combination therapy in African-Americans.
- Discuss various types of combination therapy.
- Review the potential benefits of using combination therapy.
- Prescribe combination therapy.

### PROGRAM AGENDA

- 7:00 PM **Combination Therapy Rationale**  
*Michael A. Moore, M.D., Danville, Virginia, USA*
- 7:30 PM **Combination Therapy in African-Americans**  
*Sheila Garris, M.D., Norfolk, Virginia, USA*
- 8:00 PM **Potential Benefits of Using Combination Therapy of an ARB and Calcium Channel Blocker**  
*Christoph Schindler, M.D., Dresden, Germany*
- 8:30 PM **Panel Discussion**  
*Chair and Faculty*
- 9:00 PM **ADJOURN**

---

*A light buffet will be held beginning at 6:30 pm in the corridor outside of Ponciana 3 & 4.*

THE PROGRAM COMMITTEE GRATEFULLY ACKNOWLEDGES AN  
UNRESTRICTED EDUCATION GRANT FROM DAIICHI SANKYO TO  
SUPPORT THIS DINNER SESSION.

## BREAKFAST SYMPOSIUM I

MONDAY, MAY 7, 2007 • 7:00 AM TO 8:00 AM

AMERICANA 3

---

### *Inflammation and Cardiovascular Disease*

**Chair:** Sofia P. Salas, M.D., Santiago, Chile

**Objectives:** At the conclusion of the activity, participants should be able to:

- Describe the components of the RAS in adipocytes.
- Compare the relationship between adipocyte RAS and CV disease.
- Articulate the clinical associations between inflammation and hypertension.

#### PROGRAM AGENDA

7:00 AM **The Renin Angiotensin System and Adipocytes**

*Lisa Cassis, Ph.D., Lexington, Kentucky, USA*

7:20 AM **Inflammation and Hypertension**

*Michael Brands, Ph.D., Augusta, Georgia, USA*

7:40 AM **Questions and Discussion**

8:00 AM **ADJOURN**

---

## BREAKFAST SYMPOSIUM II

MONDAY, MAY 7, 2007 • 7:00 AM TO 8:00 AM

AMERICANA 2

---

### *Autonomic Dysfunction*

**Chair:** Francois Abboud, M.D., Iowa City, Iowa, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Explain the basic mechanisms of autonomic regulation of blood pressure.
- Describe methods to assess sympathetic function and its role in hypertension
- Define the importance of sympatho-excitation in heart failure.
- Discuss the role of central AT<sub>1</sub> Receptors and radical stress.
- Define DEG/ENaC channels in bars (BR) and chemoreceptor (CR) activation.
- Articulate reciprocal relationship between BR and CR sensitivity.

#### PROGRAM AGENDA

7:00 AM **Role of the Sympathetic Nervous System in Obesity-Associated Hypertension**

*Italo Biaggioni, M.D., Nashville, Tennessee, USA*

7:20 AM **Heart Failure and the Autonomic Nervous System**

*Irving Zucker, Ph.D., Omaha, Nebraska, USA*

7:40 AM **Molecular Sensors of Cardiovascular Afferents**

*Francois Abboud, M.D., Iowa City, Iowa, USA*

8:00 AM **ADJOURN**

# BREAKFAST SYMPOSIUM III

MONDAY, MAY 7, 2007 • 7:00 AM TO 8:00 AM

AMERICANA 1

---

## *Peroxisome Proliferator-Activated Receptors (PPARS)*

Chair: William B. Strawn, DVM., Ph.D., Winston-Salem, North Carolina, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Explain mechanisms of transcription by PPARS.
- Discuss the role of PPARS in VSMC and in atherosclerosis.
- Describe the role of PPARS in endothelium and inflammatory diseases and their potential therapeutic use.

### PROGRAM AGENDA

- 7:00 AM **Critical Role of PPAR $\gamma$  in the Regulation of Vascular Function**  
*Curt D. Sigmund, Ph.D., Iowa City, Iowa, USA*
- 7:20 AM **Protective Effect of Pioglitazone on Inflammation and Atherosclerosis**  
*William B. Strawn, DVM., Ph.D., Winston-Salem, North Carolina, USA*
- 7:40 AM **Questions and Discussion**
- 8:00 AM **ADJOURN**

**THE PROGRAM COMMITTEE GRATEFULLY ACKNOWLEDGES  
AN UNRESTRICTED EDUCATION GRANT FROM TAKEDA  
PHARMACEUTICALS TO SUPPORT BREAKFAST SYMPOSIUM III.**

---

*Continental Breakfast served at 6:30 AM prior to  
Breakfast Sessions in the Americana Foyer*

# PLENARY SESSION I

MONDAY, MAY 7, 2007 • 8:00 AM – 10:15 AM

AMERICANA 3

---

## *CardioMetabolic Syndrome: True Syndrome or Collection of Disorders. Does It Matter for Therapeutic Intervention?*

**Chairs:** Luis Alcocer, M.D., Mexico City, Mexico  
Maria Cristina Salgado, Ph.D., Ribeirao Preto, Brazil

**Objectives:** At the conclusion of the activity, participants should be able to:

- Explain the pathophysiology of atherosclerosis.
- Recite recent updates on stem cells for treatment of cardiovascular disease.
- Describe aging as a risk factor in hypertension.
- Articulate the role of genetics in complex diseases, including the metabolic syndrome and obesity.
- Define the metabolic syndrome risk factors in children.
- Identify the emerging mechanisms that link obesity with hypertension.
- Discuss the role of adipokines in hypertension and metabolism.

### PROGRAM AGENDA

- 8:00 AM **Special Lecture: Arterial Disease and Repair**  
*Pascal L. Goldschmidt, M.D., Miami, Florida, USA*
- 8:20 AM **Genetics of the Metabolic Syndrome**  
*Carlos J. Pirola, M.D., Buenos Aires, Argentina*
- 8:40 AM **Pro: Metabolic Syndrome**  
*Suzanne Oparil, M.D., Birmingham, Alabama, USA*
- 8:55 AM **Con: Collection of Associated Disorders**  
*Ayrton Brandao, M.D., Rio de Janeiro, Brazil*
- 9:10 AM **CardioMetabolic Syndrome in Children**  
*Beatriz G. Grunfeld, M.D., Buenos Aires, Argentina*
- 9:30 AM **Obesity, Adipokines, and Hypertension**  
*John Hall, Ph.D., Jackson, Mississippi, USA*
- 9:50 AM **Dietary Therapy of Obesity: An Emperor with No Clothes**  
*Allyn L. Mark, M.D., Iowa City, Iowa, USA*
- 10:15 AM **ADJOURN**

THE PROGRAM COMMITTEE GRATEFULLY ACKNOWLEDGES AN  
UNRESTRICTED EDUCATION GRANT FROM MERCK, SHARPE,  
AND DOHME FOR SUPPORT OF THIS SESSION.

# SYMPOSIUM A

MONDAY, MAY 7, 2007 • 10:15 AM – 12:30 PM

AMERICANA 3

---

## *Hypertension and Cardio-Renal Mechanisms The Ibero-American Perspective*

**Chairs:** Luis M. Ruilope, M.D., Madrid, Spain  
Luis I. Juncos, M.D., Cordoba, Argentina

**Objectives:** At the conclusion of the activity, participants should be able to:

- Discuss the advantage of arterial blood pressure management, and when to use it.
- Summarize the impact of different antihypertensive drugs on carbohydrate metabolism.
- Identify BP thresholds to define HTN and criteria for control.
- Describe the “High Risk Patient”, and the importance of blood pressure control.
- Identify drugs and strategies to protect against organ damage and reduce cardiovascular mortality and morbidity.
- Define microalbuminuria and cardiovascular renal risk.
- Discuss the possibility of setting up an internet-related network in the US, Central and South America of hypertension units with a common purpose of investigation.

### PROGRAM AGENDA

**10:15 AM Ambulatory Blood Pressure in the Management of Hypertension**

*Josep Redon, M.D., Valencia, Spain*

**10:35 AM Influence of the Metabolic Syndrome in Hypertensive Therapy**

*Nieves Martell, M.D., Madrid, Spain*

**10:55 AM Importance of Clinical Trials in Management of High Risk Patients**

*Antonio Coca, M.D., Ph.D., Barcelona, Spain*

**11:15 AM Microalbuminuria in Hypertension**

*Luis M. Ruilope, M.D., Madrid, Spain*

**11:35 AM Prevention of Chronic Kidney Disease Progression**

*Pedro Aranda, M.D., Ph.D., Malaga, Spain*

**11:55 AM Ibero-America Initiatives**

*Luis M. Ruilope, M.D., Madrid, Spain*

*Luis Juncos, M.D., Cordoba, Argentina*

**12:15 PM ADJOURN**

## SYMPOSIUM B

MONDAY, MAY 7, 2007 • 12:30 PM – 3:40 PM

AMERICANA 3

---

### *Non-Invasive Techniques for Cardiovascular Risk Assessment and Patient Management*

**Chairs:** John M. Flack, M.D., M.P.H., Detroit, Michigan, USA  
Beatriz G. Grunfeld, M.D., Buenos Aires, Argentina

**Objectives:** At the conclusion of the activity, participants should be able to:

- Explain non-invasive hemodynamic measurement, devices, and applications to hypertension.
- Describe the cost benefit ratio of the various hemodynamic parameter measurement methods.
- Explain the different alterations present in blood vessels in hypertension.
- Describe some of the mechanisms leading to different vascular phenotypes.
- Identify the major causes of drug treatment failure in hypertension.
- Adjust drug therapy to achieve improved volume and peripheral resistance.
- Review of the pleiotropic effects of statins in atherosclerosis and vascular disease.
- Discuss the outcomes of the ASCOT and CAFÉ studies relative to arterial stiffness.
- Determine the impact of body fat indexes on clinical practice and its relationships with hypertension.

#### PROGRAM AGENDA

- 1:00 PM **Non-Invasive Hemodynamic Measurement Devices: Background and Overview**  
*Ronald D. Smith, M.D., Winston-Salem, North Carolina, USA*
- 1:20 PM **Hemodynamics: Cardiac Output – Total Peripheral Resistance**  
*Hugo P. Baglivo, M.D., Buenos Aires, Argentina*
- 1:40 PM **Vascular Hemodynamics as a Guide to Antihypertensive Therapeutic Selections**  
*John M. Flack, M.D., M.P.H., Detroit, Michigan, USA*
- 2:00PM **Vascular Phenotypes in Hypertension**  
*Ernesto Schiffrin, M.D., Ph.D., Montreal, Quebec, Canada*
- 2:20 PM **Managing Resistant Hypertension**  
*Stephen Textor, M.D., Rochester, Minnesota, USA*
- 2:40 PM **Effect of Statins on Vascular Function**  
*Stephen Glasser, M.D., Birmingham, Alabama, USA*
- 3:00 PM **Risk Intervals or Cut-off Points for Central Obesity: Impact in Hypertension**  
*Martin Rosas-Peralta, M.D., Mexico City, Mexico*
- 3:20 PM **Questions and Discussion**
- 3:40 PM **ADJOURN**

---

*A box lunch will be served from 12:30 PM-1:00 PM in the Americana Foyer.*

THE PROGRAM COMMITTEE GRATEFULLY ACKNOWLEDGES AN  
UNRESTRICTED EDUCATION GRANT FROM CARDIODYNAMICS  
FOR PARTIAL SUPPORT OF THIS SESSION.

# SYMPOSIUM C

MONDAY, MAY 7, 2007 • 12:30 PM – 3:40 PM

AMERICANA 2

---

## *Blockade of the Renin System at the Point of Activation*

**Chairs:** Gregory Fink, Ph.D., East Lansing, Michigan, USA  
Oscar A. Carretero, M.D., Detroit, Michigan, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Define new concepts related to cell plasticity and homeostasis of blood pressure.
- Describe the role of renin cells in vascular growth.
- Articulate renin inhibition as part of optimization.
- Identify the role of renin in the generation of angiotensin peptides.
- List the number of factors that regulate the production of renal and tissue renin.
- Explain how chemical inhibition of renin alters the production of angiotensin II
- Discuss the role of intracellular RAS components in cardiovascular growth regulation.
- Describe the effects of RAS inhibitors on the intracellular action of RAS components.
- List the pharmacologic differences between renin inhibitors and other blockers of the RAAS.
- Discuss the antihypertensive effects of renin inhibitors

### PROGRAM AGENDA

- 1:00 PM Renin Development**  
*Ariel Gomez, M.D., Charlottesville, Virginia, USA*
- 1:20 PM Renin Inhibitors-Revisited**  
*Norman K. Hollenberg, M.D., Ph.D., Boston, Massachusetts, USA*
- 1:40 PM Biochemical Physiology of the Renin Angiotensin System**  
*Carlos M. Ferrario, M.D., Winston-Salem, North Carolina, USA*
- 2:00PM Intracellular Angiotensin and Intracrine Physiology**  
*Richard Re, M.D., New Orleans, Louisiana, USA*
- 2:20 PM Renin Angiotensin System in Metabolic Syndrome and Insulin Resistance**  
*Brent Egan, M.D., Charleston, South Carolina, USA*
- 2:40 PM Clinical Aspects of Renin Inhibitors**  
*Alan H. Gradman, M.D., Pittsburg, Pennsylvania, USA*
- 3:00 PM Modern Blockade of RAS-What Clinicians Should Expect**  
*Artur Ribeiro, M.D., Sao Pablo, Brazil*
- 3:20 PM Questions and Discussion**  
*Panel Discussion*
- 3:40 PM ADJOURN**

---

*A box lunch will be served from 12:30 PM-1:00 PM in the Americana Foyer.*

# SYMPOSIUM D

MONDAY, MAY 7, 2007 • 4:00 PM – 5:30 PM

AMERICANA 2

---

## *Angiotensin Peptides and Functions*

**Chairs:** Jose Fuchs, M.D., San Jose, Costa Rica  
Gabriel Navar, Ph.D., New Orleans, Louisiana, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Identify the components of the renin-angiotensin system.
- Identify the unique function of AT<sub>2</sub> receptors.
- Discuss actions of the renal renin angiotensin system.
- Distinguish the forms and actions of ACE vs ACE2.
- Define the actions of RAAS blockade of the kidney.
- Identify the novel roles of Angiotensin II in the brain.
- Describe the potential novel therapeutic effects of AT<sub>1</sub> receptor antagonists in the brain.
- Define the role of the receptor *mas* in the control of cardiovascular function.

### PROGRAM AGENDA

- 4:00 PM ACE2 and Renal Function**  
*Mark C. Chappell, Ph.D., Winston-Salem, North Carolina, USA*
- 4:20 PM Anti-ischemic and Anti-inflammatory Effects of Angiotensin II AT<sub>1</sub> Receptor Antagonist in the Brain**  
*Juan Saavedra, MD., Bethesda, Maryland, USA*
- 4:40 PM The *mas* Receptor**  
*Robson A. S. Santos, M.D., Belo Horizonte, Brazil*
- 5:00 PM Role of AT<sub>2</sub> Receptors in the Control of Blood Pressure**  
*Robert M. Carey, M.D., Charlottesville, Virginia, USA*
- 5:30 PM ADJOURN**

# SYMPOSIUM E

MONDAY, MAY 7, 2007 • 4:00 PM – 5:30 PM

AMERICANA 1

---

## *Clinical Hot Topics*

**Chairs:** David Averill, Ph.D., Portsmouth, Dominica  
Gary Schwartz, M.D., Rochester, Minnesota, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Discuss why pulse pressure is a better correlate to arterial stiffness.
- Explain stress and basal blood pressure levels.
- Discuss the factors related to cerebrovascular disease and hypertension.
- Define white-coat hypertension, and its relationship with ischemic brain injury

### PROGRAM AGENDA

- 4:00 PM **Ambulatory Pulse Pressure is a Better Correlate to Arterial Stiffness than the New Ambulatory Arterial Stiffness Index in Patients with Resistant Hypertension**  
*Elizabeth Muxfeldt, M.D., Rio de Janeiro, Brazil*
- 4:15 PM **Relationships of “Masked” and “White-Coat” Hypertension with Ischemic Brain Injury**  
*Gary L. Schwartz, M.D., Rochester, Minnesota, USA*
- 4:30 PM **Stress and Basal Blood Pressure Levels, Not a Family History of Hypertension, Determine Cardiovascular Reactivity and Recovery to Stress**  
*Carlos Figueroa-Lopez, Mexico City, Mexico*
- 4:45 PM **Plasma Resistin Levels are Associated with Urinary Albumin Excretion in Hypertensive Adults**  
*Allison Ellington, Rochester, Minnesota, USA*
- 5:00 PM **Association of Microcirculatory and Conduit Arterial Stiffness in Asymptomatic Adults from the Community**  
*Iftikhar J. Kullo, M.D., and A. Rauoof Malik, M.D., Rochester, Minnesota, USA*
- 5:15 PM **Cerebrovascular Disease and Hypertension-HUC 2003**  
*M. M. Perez-Vasquez, Caracas, Venezuela*
- 5:30 PM **ADJOURN**

# DINNER SYMPOSIUM II

MONDAY, MAY 7, 2007 • 6:30 PM – 9:00 PM

AMERICANA 3

---

## *Blood Pressure and Goal Rates: Binding it All Together*

**Chairs:** Martin Didier, M.D., Nassau, Bahamas  
Conville Brown, M.D., Nassau, Bahamas

**Objectives:** At the conclusion of the activity, participants should be able to:

- Describe the role of nitric oxide in the hemostasis of the vascular wall.
- Identify clinical situations in which there is vascular imbalance between nitric oxide and Ang II.
- Explain antiatherosclerotic actions of antihypertensive treatment.
- Describe angiotensin receptor blockers and mechanisms of action.
- Identify the prehypertensive stage as defined in JNC-7.
- Explain why the prehypertensive stage is a predictor of future hypertension and vascular disease
- Define the effects of ARBs as monotherapy and in combination therapy.
- Compare ACE inhibitors and ARBs in cardiovascular risk outcomes.
- Identify structure-activity relationships (SAR) of AT<sub>1</sub>-R blockers.
- Discuss how SAR links to in vitro pharmacology of AT<sub>1</sub>-R blockers.
- Explain the difference between surmountable and insurmountable drugs

### PROGRAM AGENDA

- 6:30 PM**    **Interaction of Nitric Oxide and Angiotension II**  
*Leopoldo Rajj, M.D., Miami, Florida, USA*
- 6:50 PM**    **What Do Trials in ARBs Tell Us?**  
*Domenic Sica, M.D., Richmond, Virginia, USA*
- 7:10 PM**    **Effect of ARB Therapy on Atherosclerosis: The MORE Study**  
*Klaus O. Stumpe, M.D., Bonn, Germany*
- 7:30 PM**    **Do Early Pathological Findings Precede Hypertension?**  
*Carlos Ferrario, M.D., Winston-Salem, North Carolina, USA*
- 7:50 PM**    **Efficacy of Angiotensin II Receptor Blockers**  
*Michael Moore, M.D., Danville, Virginia, USA*
- 8:10 PM**    **Pharmacodynamics of ARBs**  
*Georges Vauquelin, Ph.D., Brussels, Belgium*
- 8:30 PM**    **Questions and Discussion**
- 9:00 PM**    **ADJOURN**

---

*Buffet dinner will be served beginning at 6:00 PM in the Americana Foyer*

**THE PROGRAM COMMITTEE GRATEFULLY ACKNOWLEDGES AN  
UNRESTRICTED EDUCATION GRANT FROM DAIICHI SANKYO AND  
PARTIAL SUPPORT FROM SCHERING PLOUGH FOR THIS SESSION.**

## BREAKFAST SYMPOSIUM IV

TUESDAY, MAY 8, 2007 • 7:00 AM – 7:50 AM

AMERICANA 3

---

### *Sex Hormones and the Vasculature*

**Chairs:** J. R. Haywood, Ph.D., M.S., East Lansing, Michigan, USA  
Jane F. Reckelhoff, Ph.D., Jackson, Mississippi, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Describe endothelial dysfunction.
- Define current concepts in the pathophysiology of pre-eclampsia.
- Discuss mechanisms of endothelial dysfunction in pre-eclampsia.
- Explain the role of cytokines and angiogenic factors in pre-eclampsia.
- Discuss the effects of sex hormones on the vasculature.

#### PROGRAM AGENDA

- 7:00 AM **Endothelial Dysfunction**  
*Maria Helena Carvalho, Ph.D., Sao Paulo, Brazil*
- 7:20 AM **Endothelial Dysfunction in Pre-eclampsia: An Emerging Role for Cytokines and Angiogenic Factors**  
*Joey Granger, Ph.D., Jackson, Mississippi, USA*
- 7:40 AM **Questions and Discussion**
- 7:50 AM **ADJOURN**
- 

## BREAKFAST SYMPOSIUM V

TUESDAY, MAY 8, 2007 • 7:00 AM – 7:50 AM

AMERICANA 2

---

### *Ang-(1-7), ACE2 and the mas Receptor*

**Chairs:** Robson A. S. Santos, Ph.D., Belo Horizonte, Brazil  
Jorge Jalil, M.D., Santiago, Chile

**Objectives:** At the conclusion of the activity, participants should be able to:

- Review current concepts on angiotensin peptides and cancer growth.
- Discuss molecular mechanisms involved in Ang-(1-7) inhibition of cancer growth.
- Explain the concept of systemic gene transfer as a strategy for CV protection.
- Describe the concept that activation/overexpression of ACE2 can protect the heart from hypertension-induced damage.

#### PROGRAM AGENDA

- 7:00 AM **Anti-tumoral Effects of Ang-(1-7)**  
*Patricia E. Gallagher, Ph.D., Winston-Salem, North Carolina, USA*
- 7:20 AM **Cardiovascular Protection by ACE2: A New Paradigm**  
*Mohan K. Raizada, Ph.D., Gainesville, Florida, USA*
- 7:40 AM **Questions and Discussion**
- 7:50 AM **ADJOURN**
- 

*Continental Breakfast served at 6:30 AM prior to Breakfast Sessions in the Exhibition Hall, Americana 4*

# FEATURED SESSIONS I

TUESDAY, MAY 8, 2007 • 8:00 AM – 9:40 AM

AMERICANA 3

---

## *Vascular Signaling in Hypertension*

**Chairs:** Kathryn Sandberg, Ph.D., Washington, D.C., USA  
R. Clinton Webb, Ph.D., Augusta, Georgia, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Explain oxidative stress on cardiovascular disease.
- Identify the role of mitochondria.
- Describe natriuretic peptide receptors.
- Discuss signaling mechanisms.
- Review the effects of angiotensin peptides on vascular smooth muscle cell growth.
- Describe how angiotensin peptides regulate vascular growth.
- Identify components of the RhoA/Rho Kinase signaling cascade.
- List the sex chromosome effects that regulate angiotensin receptor regulation, angiotensin converting enzyme 2 (ACE2), and mean arterial pressure.

### PROGRAM AGENDA

- 8:00 AM Oxidative Stress and Mitochondrial Function**  
*Leon Ferder, M.D., Ph.D., Ponce, Puerto Rico*
- 8:20 AM Natriuretic Peptide Signaling in the Heart and Vasculature**  
*Margot C. LaPointe, Ph.D., Detroit, Michigan, USA*
- 8:40 AM Vascular Signaling and Growth**  
*E. Ann Tallant, Ph.D., Winston-Salem, North Carolina, USA*
- 9:00 AM Rho-kinase and the Vasculature**  
*R. Clinton Webb, Ph.D., Augusta, Georgia, USA*
- 9:20 AM Sex Chromosome Effects in Angiotensin II-induced Hypertension**  
*Kathryn Sandberg, Ph.D., Washington, D.C., USA*
- 9:40 AM ADJOURN**

---

*Refreshment Break in Exhibit Hall*

## FEATURED SESSION II

TUESDAY, MAY 8, 2007 • 8:00 AM – 9:40 AM

AMERICANA 2

---

### *What is the Main Target Tissue for Angiotensin II in Hypertension?*

**Chairs:** Gregory Fink, Ph.D., Lansing, Michigan, USA  
Mariana Morris, Ph.D., Dayton, Ohio, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Discuss current knowledge and controversy concerning the primary site of action of angiotensin II.
- Define brain Ang II signaling.
- Describe the introduction to oxidant stress in the brain.
- Identify integration of brain, vascular, kidney Ang II systems.
- Describe the intrarenal localization of angiotensin II receptors, angiotensinogen and renin.
- Explain the multiple actions of angiotensin II on renal vascular and tubular cells.
- Describe the vascular phenotype in hypertension.
- Explain how Ang II influences vascular function and structure in hypertension.

#### PROGRAM AGENDA

- 8:00 AM** Introduction and Long-term Actions of Angiotensin II  
*Gregory Fink, Ph.D., East Lansing, Michigan, USA*
- 8:20 AM** Role of the Brain in Ang II Dependent Hypertension  
*Robin L. Davisson, Ph.D., Ithaca, New York, USA*
- 8:40 AM** Unique Angiotensin II Augmentation Mechanisms in Kidneys  
*Gabriel Navar, Ph.D., New Orleans, Louisiana, USA*
- 9:00 AM** The Vasculature as the Main Target Tissue for Angiotensin II  
*Rhian M. Touyz, M.D., Montreal, Quebec, Canada*
- 9:20 AM** Questions and Discussion
- 9:40 AM** ADJOURN

---

*Refreshment Break in Exhibit Hall*

## FEATURED SESSION III

TUESDAY, MAY 8, 2007 • 7:00 AM – 10:00 AM

AMERICANA 1

---

### *Lipids and the Management of CV Risk Reduction*

**Chairs:** Dan Wise, M.D., Charlotte, North Carolina, USA  
William C. Cromwell, M.D., Charlotte, North Carolina, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- List the markers considered for cardiovascular risk stratification.
- Discuss advanced lipid testing as a biomarker.
- Define HDL and its significance in the management of CV risk reduction.
- Identify the methods used for CV risk reduction.
- Explain the metabolic syndrome and dyslipidemia.
- Articulate the optimal approach to reduce CV risk in patients with the metabolic syndrome and dyslipidemia.

#### PROGRAM AGENDA

- 7:00 AM Clinical Options for Management of Low HDL Cholesterol Syndromes**  
*Ronald Goldberg, M.D., Miami, Florida, USA*
- 7:40 AM Current Approaches for Risk Stratification of CHD Risk**  
*Thomas A. Barringer, M.D., Charlotte, North Carolina, USA*
- 8:20 AM Clinical Considerations in Advanced Lipoprotein Testing and Biomarkers**  
*William C. Cromwell, M.D., Charlotte, North Carolina, USA*
- 9:00 AM Current Perspectives in Evaluation and Management of Patients with Metabolic Syndrome**  
*Daniel Wise, M.D., Charlotte, North Carolina, USA*
- 9:40 AM Questions and Discussion**
- 10:00 AM ADJOURN**

---

*Refreshment Break in Exhibit Hall*

THE PROGRAM COMMITTEE GRATEFULLY ACKNOWLEDGES  
AN UNRESTRICTED EDUCATION GRANT FROM ASTRA-ZENECA  
TO PARTIALLY SUPPORT THIS SESSION AND THE SOUTHEAST  
LIPID ASSOCIATION (SELA), A CHAPTER OF THE NATIONAL  
LIPID ASSOCIATION FOR SPONSORING THIS SESSION.

# CONCURRENT ORAL SESSION I

TUESDAY, MAY 8, 2007 • 10:15 AM – 12:20 PM

AMERICANA 3

---

## *Mechanisms of Blood Pressure Regulation*

**Chairs:** Carmen Hinojosa-Laborde, Ph.D., San Antonio, Texas, USA  
Nancy L. Kanagy, Ph.D., Albuquerque, New Mexico, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Articulate the systemic cardiovascular effects of intermittent hypoxia.
- Describe the effects of intermittent hypoxia on vascular reactivity.
- Discuss the potential mechanisms underlying vascular changes in chronic intermittent hypoxia.
- Explain baroreflex impairment.
- Describe vascular resistance in aging.

### PROGRAM AGENDA

- 10:15 AM **State of the Art Lecture-Intermittent Hypoxia-induced Hypertension: Lessons for Sleep Apnea**  
*Nancy L. Kanagy, Ph.D., Albuquerque, New Mexico, USA*
- 10:35 AM **Interactions between Losartan and Fructose Consumption: Enhanced Depressor Response**  
*Danielle Senador, Dayton, Ohio, USA*
- 10:50 AM **Direct Cardiac Anti-Inflammatory and Anti-Hypertropic Effects of Moxonidine**  
*Ahmed Menaouar, Canada*
- 11:05 AM **Treatment of Obstructive Sleep Apnea Improved Arterial Stiffness: A Randomized Study**  
*Luis Bortolotto, Sao Paulo, Brazil*
- 11:20AM **Endogenous Activity of the CNS Melanocortin System Contributes to the Elevated Arterial Pressure in Spontaneously Hypertensive Rats**  
*Alexandre Alves da Silva, Jackson, Mississippi, USA*
- 11:35 AM **Effects of Central Sodium on Mineralocorticoid Receptors (MR) and Epithelial Sodium Channels (ENAC) in Rat Brain**  
*Hong-Wei Wang, Ottawa, Ontario, Canada*
- 11:50 AM **Role of Baroreflex Impairment and Blood Pressure Variability in Cardiac Hypertrophy in Spontaneously Hypertensive Rats**  
*Ivana Cinthya de Moraes da Silva, Sao Paulo, Brazil*
- 12:05 PM **Mechanism of Vascular Resistance in Aging**  
*Ivonne Schulman M.D., Miami, Florida, USA*
- 12:20 PM **ADJOURN**

# CONCURRENT ORAL SESSION II

TUESDAY, MAY 8, 2007 • 10:15 AM – 12:25 PM

AMERICANA 2

---

## Nitric Oxide, Oxidative Stress and Vascular Health

**Chairs:** Fernando Elijovich, M.D., Temple, Texas, USA  
Lisete C. Michelini, Ph.D., Sao Paulo, Brazil

**Objectives:** At the conclusion of the activity, participants should be able to:

- Describe the three element interactions that participate in the genesis of essential hypertension.
- Discuss views on the intracellular signaling elements that increase superoxide in hypertension.
- Explain the rationale underlying the treatment of hypertension.
- Distinguish between the effects of nitric oxide on pre-capillary vessels (vascular resistance) and post-capillary vessels (permeability-inflammation).
- Describe how nitric oxide may play a permissive rather than an active role in some microvascular effects.

### PROGRAM AGENDA

- 10:15 AM State of the Art Lecture-Role of Oxidative Stress in Angiotensin-induced Hypertension**  
*Carlos Romero, M.D., Rochester, Minnesota, USA*
- 10:35 AM Invited Presentation-Microvasculature and Nitric Oxide**  
*Mauricio P. Boric, Ph.D., Santiago, Chile*
- 10:55 AM The Time-Dependent Effect of L-NAME on Endothelial NOS Expression in the Heart & Brain**  
*Olga Pechanova, Bratislava, Slovak Republic*
- 11:10 AM Deficiency in Endothelial Nitric Oxide Synthase Activity Leads to Enhanced Superoxide Activity that Contributes to the Development of Salt Sensitive Hypertension**  
*Libor Kopkan, New Orleans, Louisiana, USA*
- 11:25 AM Cardiac Remodeling of Rats with Hypertension due to Nitric Oxide Synthesis Inhibition: Effects of Olmesartan and Allopurinol**  
*Daniel Arthur B. Kasal, Rio de Janeiro, Brazil*
- 11:40 AM Endothelial Cell-regulated Vascular Smooth Muscle Cell Production of Reactive Oxygen Species does not Involve Nitric Oxide in a Co-culture System**  
*Shaoping Xu, Ottawa, Ontario, Canada*
- 11:55 AM Aldosterone Suppresses Insulin Signaling via Reactive Oxygen Species and SRC-dependent Downregulation of Insulin Receptor Substrate-1 in Rat Vascular Smooth Muscle Cells**  
*Hirofumi Hitomi, Kagawa, Japan*
- 12:10 PM Enhanced Nitric Oxide-mediated Vascular Relaxation in Caveolin-1 Deficient Mice on High Salt Diet**  
*Luminita H. Pojoga, Boston, Massachusetts, USA*
- 12:25 PM ADJOURN**

# CONCURRENT ORAL SESSION III

TUESDAY, MAY 8, 2007 • 10:15 AM – 12:20 PM

AMERICANA 1

---

## *Hot Topics in Cardiovascular Health*

**Chairs:** Barbara Alexander, Ph.D., Jackson, Mississippi, USA  
David Averill, Ph.D., Portsmouth, Dominica

**Objectives:** At the conclusion of the activity, participants should be able to:

- Describe the fetal environment and its affect on the development of cardiovascular disease in later life.
- Articulate the role of gender in the fetal programming of hypertension.
- Explain the biological significance of ACE polymorphisms on angiotensin levels.
- Compare the possible relationships of ACE polymorphisms on cardiovascular remodeling.
- Describe the relationship between angiotensin (1-7) and cardiac function.
- Define the adverse cardiovascular risk profile of hypertensive end-stage renal disease.
- Demonstrate the dissociation between the effects of nocturnal hemodialysis on endothelial function, cardiovascular risk markers, and plasma ADMA.
- Articulate the function of N-domain ACEs in the nephron and the interaction and localization with Ang (1-7) and Ang II
- Describe the clinical impact of islet transplantation.

### PROGRAM AGENDA

- 10:15 AM **Invited Presentation: Pre-natal Programmed Hypertension**  
*Barbara Alexander, Ph.D., Jackson, Mississippi, USA*
- 10:35 AM **Invited Presentation: ACE Polymorphisms, Ang-(1-7) and Cardiovascular Remodeling**  
*Jorge Jalil, M.D., Santiago, Chile*
- 10:50 AM **Invited Presentation: Endothelial Dysfunction and ADMA in End-Stage Renal Disease: Insights Nocturnal Hemodialysis**  
*John S. Floras, M.D., Ph.D., Toronto, Ontario, Canada*
- 11:05 AM **Invited Presentation: Can Islet Cell Transplant Cure Type I Diabetes**  
*Elizabeth Fenjves, Ph.D, Miami, Florida, USA*
- 11:20 AM **Invited Presentation: N-domain Angiotensin Converting Enzymes along the Rat Nephron**  
*Dulce Elena Casarini, Ph.D., Sao Paulo, Brazil*
- 11:35 AM **COX-1 from Bone Marrow-Derived Cells Promotes Angiotensin II-Dependent Hypertension**  
*Tracy A. Henriques, Durham, North Carolina, USA*
- 11:50 AM **Oxytocin and Myogenesis**  
*Marek Jankowski, Montreal, Quebec, Canada*
- 12:05 PM **Improved Ventricular Function by Blockage of the AT1 Receptor is Associated with Increased ACE<sub>2</sub> and Higher Levels of Angiotensins (1-9) and (1-7) in the Late Remodeling Post-myocardial Infarction**  
*Maria Paz Ocaranza, Santiago, Chile*
- 12:20 PM **ADJOURN**

# INTERACTIVE WORKSHOPS I – III

TUESDAY, MAY 8, 2007 • 10:15 AM – 12:20 PM

ONE HOUR EACH, REPEATED ONCE (10:15 -11:15; 11:20-12:20)

---

## *Workshop # 1 - Calculating CV Risk in the Clinic*

MEETING ROOM - PONCIANA 1

**Faculty:** Mark Houston, M.D., M.P.H., M.S., Nashville, Tennessee, USA  
Daniel Lackland, Dr. P.H., Charleston, South Carolina, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Calculate CV risk using the COSEHC risk tool.
- Describe the mechanisms of calculating CVD risk.
- Explain the differences between relative and absolute risk.
- Articulate the components of CVD risk equations.
- Describe the strengths and weaknesses of CVD risk estimates.

## *Workshop # 2 - Managing Hyperlipidemia in Children and Adults*

MEETING ROOM - PONCIANA 2

**Faculty:** Daniel Wise, M.D., Charlotte, North Carolina, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Risk stratify patients to appropriately apply treatment.
- Set appropriate goals for lipid management.
- Use combination therapy to achieve goals.

## *Workshop # 3 - Sexual Dysfunction in the Hypertensive Patient*

MEETING ROOM - PONCIANA 3

**Faculty:** Kevin Billups, M.D., Savage, Minnesota, USA  
Kathy Jones, A.C.N.P., Charlotte, North Carolina, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Explain why erectile dysfunction (ED) is often an early marker for cardiometabolic disease.
- Describe why risk factor assessment is crucial to the evaluation of men with ED.
- Prescribe treatment options for men with ED and hypertension.
- Discuss diagnosis of endothelial disease with ED patients.
- Describe treatment approaches for hypertensive ED patients.

# INTERACTIVE WORKSHOPS IV – V

TUESDAY, MAY 8, 2007 • 10:15 AM – 12:20 PM

ONE HOUR EACH, REPEATED ONCE (10:15 -11:15; 11:20-12:20)

---

## *Workshop # 4 - Managing Hypertension in African-Americans*

MEETING ROOM - PONCIANA 4

**Faculty:** Shelia Garris, M.D., Norfolk, Virginia, USA  
James Reed, M.D., Atlanta, Georgia, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Compare/contrast comorbidities of HTN in African-Americans.
- Identify physiologic differences in treating HTN in African-Americans.
- Explain the social/economical/cultural differences that affect ability to control HTN in African-Americans
- Discuss differences in prevalence of HTN in African Americans.
- Recommend more effect treatment regimens.

## *Workshop # 5 - Case Management of the Patient with Hypertension and Cardiovascular Disease*

MEETING ROOM - COWRIE 1

**Faculty:** Angela Hallman, R.N., Charlotte, North Carolina, USA  
Francis Williams, R.N., M.S., Charlotte, North Carolina, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Apply JNC-7 guidelines to patients with hypertension and CVD.
- Describe complexities of hypertension in the metabolic syndrome patient.
- Use therapeutic lifestyle change modalities to optimize care of the hypertensive and CVD patient.

**THE PROGRAM COMMITTEE GRATEFULLY ACKNOWLEDGES  
AN UNRESTRICTED EDUCATION GRANT FROM  
PFIZER PHARMACEUTICALS FOR SUPPORT  
OF THESE INTERACTIVE WORKSHOPS.**

# SPECIAL LUNCHEON I

TUESDAY, MAY 8, 2007 • 12:30 PM – 1:45 PM

AMERICANA 3

---

## *Hot Topics in Hypertension Research*

**Chairs:** Jose. E. Krieger, M.D., Ph.D., Sao Paulo, Brazil  
Curt Sigmund, Ph.D., Iowa, City, Iowa, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Disassemble a complex phenotype.
- Identify candidate genes for hypertension.
- Assess the influence of small gene effects on complex phenotypes.
- Articulate the applications of transgenic mice to hypertension research.
- Describe approaches for generating knockout mice.
- Define the limitations of transgenic mouse models of human disease.
- Review Ca<sup>2+</sup> signal transduction pathways in vascular smooth muscle cell
- Summarize evidence supporting an important role of the ADP ribosyl cyclase/ryanodine receptor pathway in Ca<sup>2+</sup> signaling in afferent arteriolar vascular smooth muscle cells *in vitro* and acute vasoconstriction of renal resistance arterioles *in vivo*.

### PROGRAM AGENDA

**12:30 PM Genetics of Hypertension**

*Jose E. Kreiger, M.D., Ph.D., Sao Paulo, Brazil*

**12:50 PM Knockout Models of Hypertension**

*Thomas M. Coffman, M.D., Durham, North Carolina, USA*

**1:10 PM The RAS & Renin Autoregulation in Hypertension**

*William J. Arendshorst, Ph.D., Chapel Hill, North Carolina, USA*

**1:30 PM Questions and Discussion**

**1:45 PM ADJOURN**

---

*Pick up box lunch prior to start of session in the Exhibition Hall Americana 4*

## SPECIAL LUNCHEON II

TUESDAY, MAY 8, 2007 • 12:30 PM – 1:45 PM

AMERICANA 2

---

### *Obesity and Metabolism*

**Chairs:** Allyn L. Mark, M.D., Iowa City, Iowa, USA  
Dulce Elena Casarini, Ph.D., Sao Paulo, Brazil

**Objectives:** At the conclusion of the activity, participants should be able to:

- Describe the role of angiotensin receptors in mediating hypertension in diabetes.
- Discuss the role that a high fructose diet has in the etiology of glucose intolerance.
- Explain the means for testing activation of sympathetic nervous system.
- Describe the role of the brain renin angiotensin system in mediating the cardiovascular complications of insulin resistant diabetes

#### PROGRAM AGENDA

- 12:30 PM **Invited Presentation-AT<sub>1</sub> Receptors and Diabetes**  
*Mariana Morris, Ph.D., Dayton, Ohio, USA*
- 12:50 PM **Genetic Variants of Clock Transcription Factor are Associated with Susceptibility to Obesity and Hypertension in Individuals with Metabolic Syndrome**  
*Silvia Sookian, Buenos Aires, Argentina*
- 1:05 PM **Characterization of Vascular Reactivity after Rosiglitazone Treatment**  
*Christoph Schindler, M.D., Dresden, Germany*
- 1:20 PM **Thioredoxin-interacting Protein Genetic Variation is Associated with Diabetes in the General Population**  
*Jose Krieger, M.D., Sao Paulo, Brazil*
- 1:35 PM ***mas* Deficiency in FVB/N Mice Produces Marked Changes in Lipidic and Glycemic Metabolism**  
*Sergio Henrique Sousa Santos, Belo Horizonte, Brazil*
- 1:50 PM **ADJOURN**

---

*Pick up box lunch prior to start of session in the Exhibition Hall Americana 4*

# SPECIAL LUNCHEON III

TUESDAY, MAY 8, 2007 • 12:30 PM – 1:45 PM

AMERICANA 1

---

## *Mechanisms of Cardiovascular Fibrosis*

**Chairs:** Richard Roman, Milwaukee, Wisconsin, USA

**Objectives:**

- Identify the relevance of myocardial fibrosis in the pathophysiology of hypertensive heart disease.
- Discuss the relationship between fibrillar collagen turnover and myocardial fibrosis
- Describe the evidence supporting a role for the RAS systems in alterations of collagen turnover in the heart.
- Describe the relationship of nitroso-redox balance on heart failure and hypertrophy.

### PROGRAM AGENDA

- 12:30 PM **Cardiac Fibrosis in Hypertension**  
*Javier Diez, M.D., Ph.D., Pamplona, Spain*
- 1:00 PM **Heart Failure and Hypertrophy**  
*Joshua Michael Hare, M.D., Miami, Florida, USA*
- 1:30 PM **Questions and Discussion**
- 1:45 PM **ADJOURN**

---

*Pick up box lunch prior to start of session in the Exhibition Hall - Americana 4*

**THE PROGRAM COMMITTEE GRATEFULLY ACKNOWLEDGES AN  
UNRESTRICTED EDUCATION GRANT FROM MERCK, SHARPE,  
AND DOHME FOR SUPPORT OF THIS SESSION.**

# DINNER SYMPOSIUM III

TUESDAY, MAY 8, 2007 • 5:30 PM – 7:00 PM

AMERICANA 3

---

## *Aldosterone Blockade*

**Chair:** Emmanuel L. Bravo, M.D., Cleveland, Ohio, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Summarize recent data regarding the proinflammatory effects of aldosterone.
- Define the effects of aldosterone on the kidney and progression of kidney disease.
- Articulate the effects of aldosterone-antagonists.
- Explain the different forms of primary aldosteronism and mutation in adrenal enzymes.
- Define the role of aldosterone in podocyte injury and proteinuria.
- Describe involvement of oxidative stress in insulin resistance.
- Identify the mechanism for salt-sensitive hypertension in metabolic syndrome.

### PROGRAM AGENDA:

- 5:30 PM Aldosterone and Inflammation**  
*Nancy Brown, M.D., Nashville, Tennessee, USA*
- 5:50 PM Aldosterone and the Kidney**  
*Vito Campese, M.D., Los Angeles, California, USA*
- 6:10 PM Primary Aldosteronism and Mutations in Adrenal Enzymes**  
*Emmanuel L. Bravo, M.D., Cleveland, Ohio, USA*
- 6:30 PM Aldosterone in Hypertension and the Metabolic Syndrome**  
*Toshiro Fujita, M.D., Tokyo, Japan*
- 6:50 PM Questions and Discussion**
- 7:00 PM ADJOURN**

---

*Hors d'oeuvres will be served beginning at 5:00 PM in the Americana Foyer*

# DINNER SYMPOSIUM IV

TUESDAY, MAY 8, 2007 • 5:30 PM – 7:00 PM

AMERICANA 2

---

## *Hypertension - Lipid Connection*

**Chairs:** Mark Houston, M.D., Nashville, Tennessee, USA  
Michael A. Moore, M.D., Danville, Virginia, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Describe the pathophysiology of hypertension and hyperlipidemia in atherosclerosis.
- Discuss the implications of the ASCOT Trial in reducing the complications of acute cardiovascular disease.
- Explain the results and conclusions of combined statin and calcium channel blocker therapy related to blood pressure and cholesterol lowering.
- Describe the biological basis for additive and synergistic effects of combined lipid and blood pressure medications related to global CV risk.
- Define the importance of global risk for patients, rather than individual risk factors in isolation.
- Identify barriers to control: partial compliance and therapeutic inertia.

### PROGRAM AGENDA:

- 5:30 PM **Outcomes of the ASCOT Trial**  
*Theodore Feldman, M.D., Coral Gables, Florida, USA*
- 5:50 PM **The Avalon Trial**  
*Mark C. Houston, M.D., Nashville, Tennessee, USA*
- 6:10 PM **Global Cardiovascular Risk: Implication for Management**  
*Frans Leenen, M.D., Ph.D., Ottawa, Ontario, Canada*
- 6:30 PM **The CRUCIAL Study**  
*Abel Pavia Lopez, M.D., Mexico City, Mexico*
- 6:50 PM **Questions and Discussion**
- 7:00 PM **ADJOURN**

---

*Hors d'oeuvres will be served beginning at 5:00 PM in the Americana Foyer*

**THE PROGRAM COMMITTEE GRATEFULLY ACKNOWLEDGES  
AN UNRESTRICTED EDUCATION GRANT FROM PFIZER  
PHARMACEUTICALS FOR SUPPORT OF THIS SESSION.**

# BREAKFAST SYMPOSIUM VI

WEDNESDAY, MAY 9, 2007 • 7:00 AM – 8:00 AM

AMERICANA 3

---

## *Endocannabinoid as Therapeutic Targets in Cardiovascular Disease*

**Chairs:** George Kunos, M.D., Ph.D., Bethesda, Maryland, USA  
Luis Ruilope, M.D., Madrid, Spain

**Objectives:** At the conclusion of the activity, participants should be able to:

- Describe the biology of the endocannabinoid system, including the biosynthesis and degradation of these ligands and their signaling via CB receptors.
- Identify the cardiovascular actions of cannabinoids.
- Define the role of endocannabinoids in the regulation of blood pressure and cardiometabolic risk factors in obesity/metabolic syndrome
- Describe how endocannabinoids are metabolized.
- Discuss the possibilities of therapy based on endocannabinoid signaling.
- Discuss the effects of rimonabant in hypertensive patients with cardiometabolic risk.

### PROGRAM AGENDA

- 7:00 AM **Endocannabinoids and Hypertension**  
*George Kunos, M.D., Ph.D., Bethesda, Maryland, USA*
- 7:20 AM **Endocannabinoids and the Cerebral Circulation**  
*Cecilia J. Hillard, Ph.D., Milwaukee, Wisconsin, USA*
- 7:40 AM **CB1 Antagonist, Rimonabant, and its Effects on Na<sup>+</sup>**  
*Luis Ruilope, M.D., Madrid, Spain*
- 8:00 AM **ADJOURN**

---

*Continental Breakfast served at 6:30 AM prior to Breakfast Sessions  
in Exhibition Hall, Americana 4*

THE PROGRAM COMMITTEE GRATEFULLY ACKNOWLEDGES AN  
UNRESTRICTED EDUCATION GRANT FROM SANOFI-AVENTIS  
FOR PARTIAL SUPPORT OF THIS SESSION.

# BREAKFAST SYMPOSIUM VII

WEDNESDAY, MAY 9, 2007 • 7:00 AM – 8:00 AM

AMERICANA 2

---

## *Intracrine Renin-Angiotensin System*

**Chairs:** Kenneth M. Baker, M.D., Temple, Texas, USA  
Edgar A. Jaimes, M.D., Miami, Florida, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Explain the pathophysiology of the renin-angiotensin system.
- Discuss the local cardiac effects of angiotensin II.
- Describe the difference between intracardiac and intracrine cardiac renin-angiotensin system.
- Explain the consequences of the activation of an intracrine renin angiotensin system.

### PROGRAM AGENDA

- 7:00 AM **Intracellular Renin-Angiotensin System: A New Paradigm**  
*Kenneth M. Baker, M.D., Temple, Texas, USA*
- 7:20 AM **Pathophysiological Implications of an Intracrine Cardiac Renin-Angiotensin System**  
*Walmor De Mello, Ph.D., San Juan, Puerto Rico*
- 7:40 AM **Questions and Discussion**
- 8:00 AM **ADJOURN**

---

*Continental Breakfast served at 6:30 AM prior to Breakfast Sessions  
in Exhibition Hall, Americana 4*

# BREAKFAST SYMPOSIUM VIII

WEDNESDAY, MAY 9, 2007 • 7:00 AM – 9:30 AM

AMERICANA 1 (THIS IS A NON-CME ACTIVITY)

---

## *Her Heart Community* *Sponsored by Astellas Pharmaceuticals*

**Chairs:** Kathleen Mimmagh, M.D., Charleston, West Virginia, USA  
Bryon Batson, M.D., Hattiesburg, Mississippi, USA  
**Faculty:** Martha Gulati, M.D., Chicago, Illinois, USA  
Dan Wise, M.D., Charlotte, North Carolina, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Evaluate gender differences in heart disease prevalence, risk factors, mechanisms of disease and presentation.
- Review the reasons why diagnosis of coronary heart disease is a greater challenge in women than in men.
- Discuss issues relative to the diagnosis of heart disease using standard and new techniques.
- Summarize current guidelines for preventing CVD in women.
- Establish a consensus on the appropriate management of heart disease in women.

### PROGRAM DESCRIPTION

*Her Heart Community* provides health professionals with the latest developments in raising awareness of the importance of changing the way we look at women and cardiovascular disease. This in depth educational symposium will explore cardiovascular disease and the female-specific issues facing physicians and allied healthcare professionals relative to coronary physiology, diagnosis, risk factors, screening modalities, prevention, and medical management strategies.

The misperception is that heart disease is “a man’s problem” and lack of understanding of gender differences in heart disease can hinder effective diagnosis and treatment of Coronary Heart Disease. According to a 2005 survey, fewer than one in five physicians were aware of this fact.

Over the years there has been a dramatic increase in awareness among providers and women that heart disease is the leading cause of death among women—from 30% of women in 1997 to 57% in 2004. But more must be done to form a partnership between primary care providers and cardiologists and to alert women to the seriousness of heart disease – which all women are at risk. The goal of this program is to educate providers by raising awareness about women’s risk of heart disease, associated links and ways to improve their heart health and outcomes.

---

*Continental Breakfast served at 6:30 AM prior to Breakfast Sessions  
in Exhibition Hall, Americana 4*

**THE PROGRAM COMMITTEE GRATEFULLY  
ACKNOWLEDGES SPONSORSHIP OF THIS SESSION  
BY ASTELLAS PHARMA, US, INC.**

## FEATURED SESSIONS IV

WEDNESDAY, MAY 9, 2007 • 8:00 AM – 9:40 AM

AMERICANA 3

---

### *Eicosanoids and Mechanisms of Hypertension*

**Chairs:** William Campbell, Ph.D., Milwaukee, Wisconsin, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Define the role of heme oxygenase-derived products in mediation of vasodilatory/vasoconstrictor mechanisms.
- List the interactions linking reactive oxygen species and the heme-heme oxygenase system.
- Define how eicosanoids regulate albumin permeability.
- Explain the vascular actions of epoxygenase metabolites.
- Describe the monooxygenase derivatives of arachidonic acid.
- Explain the role of pressor/natriuretic biological systems in determining sole sensitivity of blood pressure.
- Describe the regulation of adrenal blood flow.
- Explain the coupling of adrenal dilation to steroid synthesis.
- Describe aldosterone regulation of blood pressure.

#### PROGRAM AGENDA

- 8:00 AM**    **The Heme-Heme Oxygenase System as a Regulator of Vascular Tone: Relation to Redox Status and Eicosanoids**  
*Alberto Nasjletti, M.D., Valhalla, New York, USA*
- 8:20 AM**    **20-Hydroxyeicosatetraenoic Acid and Transforming Growth Factor-beta: Role in Renal Injury**  
*Richard J. Roman, Ph.D., Milwaukee, Wisconsin, USA*
- 8:40 AM**    **Epoxide Hydrolase in Blood Pressure Regulation Vascular Signaling and Growth**  
*John D. Imig, Ph.D., Augusta, Georgia, USA*
- 9:00 AM**    **20-Hydroxyeicosatetraenoic Acid and the Mechanism of Salt-Sensitive Hypertension in Humans**  
*Fernando Elijovich, M.D., Temple, Texas, USA*
- 9:20 AM**    **Eicosanoids Couple Adrenal Vasodilation to Aldosterone Synthesis**  
*William Campbell, Ph.D., Milwaukee, Wisconsin, USA*
- 9:40 AM**    **ADJOURN**

---

*Refreshment Break in Exhibit Hall*

# FEATURED SESSIONS V

WEDNESDAY, MAY 9, 2007 • 8:00 AM – 9:40 AM

AMERICANA 2

---

## *Blood Pressure and Heart Rate Variability as CVD Risk Factors*

**Chair:** Debra I. Diz, Ph.D., Winston-Salem, North Carolina, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Describe the contribution of oxidative stress to decreased baroreflex sensitivity and autonomic imbalance in cardiovascular disease and aging.
- Distinguish effects of chronic oxidative stress in disease from autocrine role of ROS in acute modulation of baroreceptor afferent activity during physiological changes in blood pressure.
- Identify the central neural pathways and potential neurotransmitters involved in affecting peripheral sympathetic nervous system activity and arterial pressure.
- Define the mechanisms of age-related autonomic dysfunction and its contribution to the cardiometabolic syndrome.
- Define the role of autonomic nervous system in the pathophysiology of diabetes.
- Describe the central benefits of exercise training on cardiovascular control of normotensive and hypertensive individuals.

### PROGRAM AGENDA

- 8:00 AM**    **Reactive Oxygen Signaling in Baroreceptor Neuron: Disease to Ion Channel**  
*Mark W. Chappleau, Ph.D., Iowa City, Iowa, USA*
- 8:20 AM**    **Mechanism of Sympathetic Activation in Hypertension**  
*J.R. Haywood, Ph.D., M.S., East Lansing, Michigan, USA*
- 8:40 AM**    **Autonomic Dysfunction in Aging**  
*Debra I. Diz, Ph.D., Winston-Salem, North Carolina, USA*
- 9:00 AM**    **Autonomic Dysfunction in Diabetes**  
*Maria Claudia Irigoyen, M.D., Ph.D., Sao Paulo, Brazil*
- 9:20 AM**    **Exercise and Autonomic Control in Hypertension**  
*Lisete C. Michelini, Ph.D., Sao Paulo, Brazil*
- 9:40 AM**    **ADJOURN**

---

*Refreshment Break in Exhibit Hall*

# CONCURRENT ORAL SESSION IV

WEDNESDAY, MAY 9, 2007 • 10:15 AM – 12:25 PM

AMERICANA 3

---

## *Vasoactive Substances & the Kidney*

**Chairs:** Oscar A. Carretero, M.D., Detroit, Michigan, USA  
Pamela K. Carmines, Ph.D., Omaha, Nebraska, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Describe how inflammation affects the development of hypertension and target organ damage.
- Define the role of inflammation in cardiovascular and renal fibrosis.
- Define major endothelial functions.
- Describe the function of endothelial ACE.
- Identify the interactions of bradykinin.

### PROGRAM AGENDA

- 10:15 AM State of the Art Lecture: Role of Inflammation on Target Organ Damage in Hypertension**  
*Oscar A. Carretero, M.D., Detroit, Michigan, USA*
- 10:35 AM Invited Presentation: Bradykinin, ACE, and Endothelial Function**  
*John D. Catravas, Ph.D., Augusta, Georgia, USA*
- 10:55 AM Correlation Between the Diurnal/Nocturnal Blood Pressure Ratio and Renal Function in Hypertensive Patients**  
*Ramon C. Hermida, Vigo, Spain*
- 11:10 AM Expression and Function of the Calcium Sensing Receptor in Juxtaglomerular Cells**  
*Maria Cecilia Ortiz-Capisano, Detroit, Michigan, USA*
- 11:25 AM Chemokine Receptor 2b Blockade Reduces Renal Injury and Improves Autoregulatory Responsiveness in Angiotensin II/High Salt Hypertension**  
*Ahmed A. Elmarakby, Augusta, Georgia, USA*
- 11:40 AM Isoprostanes Stimulate Chloride Transport (JCl) and Prevent Nitric Oxide-induced Inhibition of JCl in the Cortical Thick Ascending Limb (cTAL) via a Protein Kinase A-Dependent Mechanism**  
*Nestor H. Garcia, Cordoba, Argentina*
- 11:55AM Expression of cGMP Phosphodiesterases in the Thick Ascending Limb (THAL)**  
*Gustavo R. Ares, Detroit, Michigan, USA*
- 12:10 PM Cardiovascular and Renal Effects of Protein Inhibition in Hypertensive Rats (SHR) on Regular and High Salt Diet**  
*Dinko Susic, New Orleans, Louisiana, USA*
- 12:25 PM ADJOURN**

# CONCURRENT ORAL SESSION V

WEDNESDAY, MAY 9, 2007 • 10:15 AM – 12:25 PM

AMERICANA 2

---

## *Pregnancy, Steroids and Hypertension*

**Chairs:** Joey Granger, Ph.D., Jackson, Mississippi, USA  
Gloria Valdes, M.D., Santiago, Chile

**Objectives:** At the conclusion of the activity, participants should be able to:

- Describe the complex components of the renin-angiotensin system, with an emphasis on Ang(1-7) and ACE2, in the utero-placenta unit at early and late pregnancy.
- Discuss the disruption of regulation of these components in a model of pregnancy induced hypertension, the reduced uterine perfusion pressure model of pregnancy.
- Describe the markers of placentation.
- Explain the relevance of placentation in the clinical presentation of pre-eclampsia.
- Identify sites of potential interventions to prevent pre-eclampsia.

### PROGRAM AGENDA

- 10:15 AM **State of the Art Lecture: Ang(1-7) and ACE2 in Early and Late Pregnancy**  
*K. Bridget Brosnihan, Ph.D., Winston-Salem, North Carolina, USA*
- 10:35 AM **Invited Presentation: Vasodilators in the Feto-Maternal Interface: Temporal Profiles and Potential Roles**  
*Gloria Valdes, M.D., Santiago, Chile*
- 10:55 AM **Contrasting Effects of Angiotensin-(1-7) on Urine Volume in Virgin and Pregnant Rats**  
*JaNae Joyner, Winston-Salem, North Carolina, USA*
- 11:10 AM **Kidneys Overexpress TNF- $\alpha$  and Signal Transducer Preelampsin I During Preelampsia-like Pregnancy**  
*John Fray, Kingston, Jamaica*
- 11:25 AM **The Administration of a Serotonin Precursor to Pregnant Rats Limits Volume Expansion and Reduces Urinary Kallikrein Activity Via 5-HT<sub>2</sub> Receptors**  
*Sofia P. Salas, Santiago, Chile*
- 11:40 AM **The Anabolic Steroids Associated with Exercise Training Impaired the Coronary Blood Flow Mediated by Adenosine Dependent Mechanism in Rats**  
*Fernanda Roberta Roque, Jundiai, Sao Paulo, Brazil*
- 11:55 AM **Influence of Ovarian Hormones on Baroreflex Sensitivity: Comparison between Female and Male Rats**  
*Iris Callado Sanches, Sao Paulo, Brazil*
- 12:10 PM **Lifetime Estrogen Replacement does not Prevent Hypertension or Extend Lifespan in DAHL Salt Sensitive Rats**  
*Carmen Hinojosa-Laborde, Ph.D., San Antonio, Texas, USA*
- 12:25 PM **ADJOURN**

# CONCURRENT ORAL SESSION VI

WEDNESDAY, MAY 9, 2007 • 10:15 AM – 12:25 PM

AMERICANA 1

---

## *Neural Mechanisms*

**Chairs:** Maria Jose Campagnole-Santos, Ph.D., Belo Horizonte, Brazil  
Maria Claudia Irigoyen, Ph.D., Sao Paulo, Brazil

**Objectives:** At the conclusion of the activity, participants should be able to:

- Describe the anatomy and physiology of the cardiac nervous system.
- Define therapeutic potential of the cardiac nervous system.
- Identify new members of the RAS family.
- Describe modulatory actions of Ang-(1-7) in the CNS.
- Explain the Ang-(1-7)/mas facilitatory effect on baroreflex.

### PROGRAM AGENDA

- 10:15 AM State of the Art Lecture: The Little Brain in the Heart**  
*J. Andrew Armour, M.D., Ph.D. Montreal, Quebec, Canada*
- 10:35 AM Invited Presentation: Counterregulatory Actions of Angiotensin (1-7)/mas Axis on Baroreflex Modulation**  
*Maria Campagnole-Santos, Ph.D., Belo Horizonte, Brazil*
- 10:55 AM Exercise Training (T) Reduces Pressure in SHR by Blunting Angiotensinogen (AOPEN) mRNA Expression within Nucleus Tractus Solitarii (NTS)**  
*Jorge Vinicius Cestari Felix, Sao Paulo, Brazil*
- 11:10 AM Hypotensive Effect of Angiotensin- (1-7) in Sinoartical Denervated Rats**  
*Mariela Gironacci, Buenos Aires, Argentina*
- 11:25 AM The Role of the P13 Kinase Signal Transduction Pathway in Nucleus Tractus Solitarii of mRen2.Lewis and (mRen2)27 Transgenic Hypertension**  
*Exazevia Logan, Winston-Salem, North Carolina, USA*
- 11:40 AM Modulation of Cardiovascular Autonomic Balance and Baroreflex Sensitivity by Renal Sympathetic Nerve in Hypertensive Rats**  
*Patricia Fiorino, Sao Paulo, Sao Paulo, Brazil*
- 11:55AM Autonomic and Cardiovascular Dysfunction in (ApoE-/-R + A + ) Mice with Chronic Congestive Heart Failure**  
*Rasna Sabharwal, Iowa City, Iowa, USA*
- 12:10 PM Expression of Neural Precursor Cell-Expressed, Developmentally Downregulated Gene, NEDD4L, in Brain and Kidney of DAHL Rats**  
*Esraa Elshahat Dergham, Ottawa, Ontario, Canada*
- 12:25 PM ADJOURN**

# INTERACTIVE WORKSHOPS VI – X

WEDNESDAY, MAY 9, 2007 • 10:15 AM – 12:20 PM

ONE HOUR EACH, REPEATED ONCE (10:15 -11:15; 11:20-12:20)

---

## *Workshop # 6 – Management of Resistant Hypertension*

MEETING ROOM: PONCIANA 1

**Faculty:** Robert Carey, M.D., Charlottesville, Virginia, USA  
David Carmouche, M.D., Baton Rouge, Louisiana, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Define when testing for secondary hypertension is appropriate.
- Distinguish pheochromocytoma from anxiety-related blood pressure excursions.
- Evaluate possible medication errors as a cause for poor blood pressure control.

## *Workshop # 7 – Combination Antihypertensive Therapy*

MEETING ROOM: PONCIANA 2

**Faculty:** Michael Prisant, M.D., Martinez, Georgia, USA  
Pavel Levy, M.D., Winston-Salem, North Carolina, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Explain why monotherapy is unlikely to achieve blood pressure control in most patients.
- Explain why not all antihypertensive medications are additive.

## *Workshop # 8 – Non-Invasive Hemodynamic Cardiovascular Assessment*

MEETING ROOM: PONCIANA 3

**Faculty:** Charles Lovell, M.D., Norfolk, Virginia, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Define the clinical utility of non-invasive hemodynamic devices in the clinical setting.
- Discuss outcome studies supporting the integration of non-invasive hemodynamic devices in clinical practice.
- Describe the concept of central pressure and its relationship to pulse wave velocity.

# INTERACTIVE WORKSHOPS VI – X

WEDNESDAY, MAY 9, 2007 • 10:15 AM – 12:20 PM

ONE HOUR EACH, REPEATED ONCE (10:15 -11:15; 11:20-12:20)

---

## *Workshop # 10 – Management of Type 2 Diabetes Mellitus*

MEETING ROOM - PONCIANA 4

**Faculty:** William Bestermann, M.D., Kingsport, Tennessee, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Describe a practical pharmacology program that works well in the majority of diabetics and some variation.

## *Workshop # 9 – Successful Weight Reduction*

MEETING ROOM - COWRIE 1

**Faculty:** Cheryl Kuhta-Sutter, R.D., Charlotte, North Carolina, USA  
Marcia Harris, R.N., Charlotte, North Carolina, USA  
Nancy Terwood, R.N., Dayton, Ohio, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Identify proven weight loss strategies.
- Evaluate different types of diets-fad diets.
- Incorporate weight loss strategies with healthy living.

THE PROGRAM COMMITTEE GRATEFULLY ACKNOWLEDGES  
AN UNRESTRICTED EDUCATION GRANT FROM  
MERCK, USA FOR SUPPORT  
OF THESE INTERACTIVE WORKSHOPS.

# SPECIAL LUNCHEON IV

WEDNESDAY, MAY 9, 2007 12:30 PM – 2:00 PM

AMERICANA 3

---

## *The Kidney as a Culprit in Hypertension*

**Chairs:** George L. Bakris, M.D., Chicago, Illinois, USA  
Alberto Nasjletti, M.D., Valhalla, New York

**Objectives:** At the conclusion of the activity, participants should be able to:

- Explain the use of RAS blocking with diuretics.
- Discuss differences in tolerability between ACEI/ARB.
- Describe data of metabolic changes of diuretics in the presence of RAS blockers.
- Explain impaired renal function and how it contributes to the development of hypertension.
- Describe the effects of various treatments on hypertension in patients with coronary artery disease.
- Discuss the role of dopamine made by the kidney in sodium balance.
- Discuss the role of gene variants in the causation of hypertension.

### PROGRAM AGENDA

- 12:30 PM ACE Inhibitors, ARBs and Diuretics**  
*George L. Bakris, M.D., Chicago, Illinois, USA.*
- 12:50 PM Kidney as a Cause of Hypertension**  
*Carlos P. Vio, M.D., Santiago, Chile*
- 1:10 PM Combination Therapy with Calcium Channel Blockers**  
*Carl Pepine, M.D., Gainesville, Florida, USA*
- 1:30 PM Dopamine and Hypertension**  
*Pedro A. Jose, M.D., Washington, D.C., USA*
- 1:50 PM Questions and Discussion**
- 2:00 PM ADJOURN**

---

*Pick up a box lunch prior to the start of the session  
in the Exhibition Hall - Americana 4*

THE PROGRAM COMMITTEE GRATEFULLY ACKNOWLEDGES AN  
UNRESTRICTED EDUCATION GRANT FROM ABBOTT  
PHARMACEUTICALS FOR SUPPORT OF THIS SESSION.

# AWARDS DINNER AND PROGRAM

WEDNESDAY, MAY 9, 2007

AMERICANA 3 AND 4

---

**5:00 PM** ..... **RECEPTION**

Room: Americana Foyer

**6:30 PM** ..... **DINNER**

**7:00 PM** ..... **PROGRAM AND AWARDS**

**GUEST SPEAKER** ..... Edward Frohlich, M.D.  
Louisiana, New Orleans, USA

“AS I SEE IT”

# BREAKFAST SYMPOSIUM VIII

THURSDAY, MAY 10, 2007 7:00 AM – 7:50 AM

AMERICANA 3

---

## *Are There Differences Among ARBs?*

**Chairs:** Jerry Miller, M.D., Kingsport, Tennessee, USA  
Richard Schuster M.D., Kettering, Ohio, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Identify stimuli to cardiac hypertrophy.
- Describe the relations between cardiac hypertrophy and stroke and other events.
- Articulate the impact of hypertrophy regression on rates of cardiovascular events.
- Define control rates for hypertension and issues that affect these rates.
- Describe the rationale from fixed dose combinations to control blood pressure control.

### PROGRAM AGENDA

**7:00 AM Preventing Target Organ Damage: Cardiac Hypertrophy and Stroke**

*Richard Devereux, M.D., New York, New York, USA*

**7:20 AM Barriers to Optimal Control of Hypertension**

*Jan N. Basile, M.D., Charleston, South Carolina, USA*

**7:50 AM ADJOURN**

# BREAKFAST SYMPOSIUM IX

THURSDAY, MAY 10, 2007 7:00 AM – 7:50 AM

POINCIANA 1 AND 2

---

## *Diabetes*

**Chairs:** James Sowers, M.D., Tucson, Arizona, USA  
Pedro A. Velasquez-Mieyer, M.D., Memphis, Tennessee, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Describe the role of Sitagliptin in Type 2 Diabetes Mellitus.
- Discuss the contributions of DPP-IV inhibitors.
- Define the epidemic of obesity and Type 2 diabetes in youth and its deleterious health impact.
- Identify adolescents at risk for obesity and related complications and diabetes.
- Conduct early screening and treatment of obese subjects at risk of diabetes and associated complications.

### PROGRAM AGENDA

**7:00 AM** Sitagliptin in Type 2 Diabetes Mellitus  
*Adam Whaley-Connell, D.O., M.S.P.H., Columbia, Missouri, USA*

**7:20 AM** Obesity and Diabetes in Adolescents  
*Pedro A. Valasquez-Mieyer, M.D., Memphis, Tennessee, USA*

**7:50 AM** Adjourn

THE PROGRAM COMMITTEE GRATEFULLY ACKNOWLEDGES  
AN UNRESTRICTED EDUCATION GRANT FROM TAKEDA  
PHARMACEUTICALS FOR SUPPORT OF THIS SESSION.

# PLENARY SESSION II

THURSDAY, MAY 10, 2007 8:00 AM – 12:15 PM

AMERICANA 3

---

## *Hypertension and Associated Risks*

**Chairs:** Paul Farrell, M.D., Jacksonville, Florida, USA  
Rafael Sequeira, M.D., Miami, Florida, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Discuss the epidemiology of hypertension and prehypertension in children/adolescents and adults.
- Describe the major risk factors associated with the development of hypertension.
- Articulate the relationship between insulin resistance and hypertension.
- Explain the mechanisms by which insulin resistance leads to hypertension.
- Discuss relationship between hypertension and small vessel disease.
- Identify mechanisms and risk factors leading to hypertensive heart failure.
- Describe the management of hypertensive heart failure.
- Define the strong association between sleep apnea and resistant hypertension.
- Prescribe when a sleep study should be ordered.
- Define the terms: hypertensive urgency, hypertensive emergency, hypertensive crisis, accelerated hypertension, and malignant hypertension.
- Compare the treatment approach to hypertensive urgencies versus hypertensive emergencies.
- Explain the pathophysiology of atherosclerosis.

### PROGRAM AGENDA

- 8:00 AM Evolving Risk of Hypertension: Childhood thru Geriatrics**  
*Shawna Nesbitt, M.D., Dallas, Texas, USA*
- 8:20 AM Insulin Resistance/Type 2 Diabetes**  
*James Sowers, M.D., Tucson, Arizona, USA*  
*(This lecture supported by an educational grant from Eli Lilly)*
- 8:40 AM Hypertension and Renal Insufficiency**  
*George Bakris, M.D., Chicago, Illinois, USA*
- 9:00 AM REFRESHMENT BREAK**
- 9:30AM Stroke and Dementia**  
*Larry Goldstein, M.D., Durham, North Carolina, USA*
- 9:50 AM Hypertensive Heart Failure**  
*Oswaldo Kohlmann, Jr., M.D., Sao Paulo, Brazil*
- 10:10 AM Sleep Disorders**  
*David Calhoun, M.D., Birmingham, Alabama, USA*
- 10:30 AM Hypertensive Urgencies and Emergencies**  
*Marc A. Pohl, M.D., Cleveland, Ohio, USA*
- 10:50 AM Questions and Discussion**
- 11:30 AM ADJOURN**

# SPECIAL LUNCH SESSION

THURSDAY, MAY 10, 2007 12:30 PM – 2:00 PM

AMERICANA 3

---

## *The Dr. William McBride Memorial Lecture*

**Chair:** Allan Goldberg, M.D., North Wales, Pennsylvania, USA

**Objectives:** At the conclusion of the activity, participants should be able to:

- Identify the current status and trends in heart disease.
- Describe the potential impact of population prevention.
- Articulate feasible approaches to population prevention.

### PROGRAM AGENDA

- 12:30 PM COSEHC Poster Awardees Oral Presentations**  
**Basic Science** - Kelly Parsons, Ph.D., Durham, North Carolina, USA  
**Clinical** - Yanbin Dong, M.D., Augusta, Georgia, USA  
**Epidemiology** - Christine Walters, Ph.D., Charleston, South Carolina, USA
- 1:15 PM Introduction of the William McBride Memorial Lecture**  
*Allan Goldberg, M.D., North Wales, Pennsylvania, USA*
- 1:30 PM LECTURE:**  
**Population Strategies to Reduce Morbidity and Mortality due to Cardiovascular Disease**  
*Augustus O. Grant, M.D., Durham, North Carolina, USA*
- 2:00 PM SCIENTIFIC SESSIONS ADJOURN**

---

*Buffet lunch served from 12:00 PM – 12:30 PM prior to start of session in Americana foyer.*

THE PROGRAM COMMITTEE GRATEFULLY ACKNOWLEDGES  
AN UNRESTRICTED EDUCATION GRANT FROM MERCK HUMAN  
HEALTH, USA FOR SUPPORT OF THIS SESSION.